The Japan tuberculosis treatment market was valued at USD 466.57 Million in 2025, driven by the increasing incidence of tuberculosis in the region. The market is anticipated to grow at a CAGR of 4.80% during the forecast period of 2026-2035, with the values likely to reach USD 745.64 Million by 2035.
Base Year
Historical Period
Forecast Period
The primary driver of the market is the expanding aging population in Japan, which is more susceptible to tuberculosis due to weakened immunity, increasing demand for early diagnosis, and long-term therapeutic care.
Recent market trends include growing adoption of rapid diagnostic techniques and molecular testing, along with rising government initiatives focused on nationwide tuberculosis screening, treatment adherence, and reducing latent TB infections among high-risk populations.
Japan's tuberculosis treatment market benefits from a robust healthcare system, strong pharmaceutical presence, and consistent public health campaigns aimed at improving awareness, early intervention, and access to affordable and effective TB medications.
Compound Annual Growth Rate
4.8%
Value in USD Million
2026-2035
*this image is indicative*
Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially impacting other organs. Tuberculosis treatment involves a multi-drug antibiotic regimen over several months to ensure complete eradication and prevent resistance. The Japan tuberculosis treatment market is supported by robust healthcare systems, aging demographics, and national efforts in disease control and prevention.
Rising Tuberculosis Incidence to Accelerate Market Growth
The increasing incidence of tuberculosis is a significant driver of market growth in Japan. As per the World Health Organization, Japan recorded a tuberculosis incidence rate of 9.3 cases per 100,000 population in 2023. This ongoing public health concern reflects the demand for effective therapies, thereby contributing to the expansion of the tuberculosis treatment market.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
Market Breakup by Therapy
Market Breakup by Dosage Form
Market Breakup by Route of Administration
Market Breakup by End User
Active TB to Dominate the Market Share Based on Disease Type
Based on disease type, the market is divided into active TB and latent TB. Among these, active tuberculosis is expected to hold a significant share of the market, driven by its higher transmission risk, symptomatic nature, and greater need for immediate medical intervention. The growing global burden of active TB cases and increased public health efforts for early detection and treatment further contribute to its dominant share in the tuberculosis treatment market.
The Japan tuberculosis treatment market shows strong regional performance, with the eastern and western regions leading due to their dense populations and well-established healthcare systems. Eastern Japan, including Tokyo and surrounding areas, drives demand through advanced medical facilities. Western Japan, particularly Osaka, contributes significantly through ongoing public health initiatives and increased awareness of tuberculosis screening and treatment.
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi, established in 1973 and headquartered in Paris, France, is a global healthcare leader committed to developing innovative treatments. In the tuberculosis treatment market, Sanofi plays a significant role through its product Priftin® (rifapentine), used in combination with isoniazid for latent tuberculosis infection. The company’s long-standing investment in tuberculosis research strengthens its impact in the region.
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson Services Inc. plays a significant role in tuberculosis treatment through its product Sirturo (bedaquiline). Approved by the U.S. FDA and European Commission in July 2024, SIRTURO® is vital for treating multidrug-resistant tuberculosis and supports global treatment protocols, including those adopted in Japan.
Otsuka Pharmaceutical Co., Ltd., established in 1964 and headquartered in Tokyo, Japan, is a global healthcare company actively involved in tuberculosis treatment. The company has developed Deltyba (delamanid), an innovative anti-tuberculosis drug used to treat multidrug-resistant TB. Through its research and development efforts, Otsuka continues to address critical needs in the tuberculosis treatment market.
GlaxoSmithKline plc, headquartered in London, United Kingdom, plays a key role in tuberculosis treatment. The company joined the PAN-TB collaboration, a global initiative aimed at developing novel, simplified, and resistance-free tuberculosis regimens. This strategic involvement supports innovation in Japan's TB treatment market, addressing complex treatment challenges and drug-resistant cases.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Novartis AG, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, and Eli Lilly and Company.
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Therapy |
|
| Breakup by Dosage Form |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share